Sector: MedicalSIRT (NASDAQ: SIRT)
Headlines
- Hercules Tech Sees Gain From Glaxo's Buy Of Sirtris
Apr 24, 2008 03:24 PM | GSK, HTGC, SIRT
- UPDATE: GlaxoSmithKline To Buy Sirtris For $720 Million
Apr 22, 2008 07:14 PM | GSK, SIRT
- GlaxoSmithKline To Buy Sirtris Pharma For $720 Million
Apr 22, 2008 05:04 PM | GSK, SIRT
- Earnings Report: 02/24/2008
Feb 25, 2008 07:23 PM | AMT, DCO, FE, GG, GLF, HSIC
- Sirtris Pharmaceuticals Presents at the American Diabetes Association's 68th Annual Scientific Sessions June 8
Jun 04, 2008 08:05 AM | SIRT
- Mergent, Inc. Announces Changes to the HealthShares(TM) Metabolic-Endocrine Disorders Index
Jun 02, 2008 05:42 PM | GSK, SIRT
- GlaxoSmithKline Successfully Completes Tender Offer for Shares of Sirtris Pharmaceuticals
Jun 02, 2008 08:55 AM | GSK, SIRT
- GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals - Jun 2 2008 4:06AM
May 02, 2008 09:01 AM | GSK, SIRT
- Sirtris Pharmaceuticals Reports First Quarter 2008 Financial Results - Jun 2 2008 4:06AM
May 01, 2008 04:38 PM | SIRT
- Genstruct and Sirtris Pharmaceuticals Win Bio-IT World's Best Practices Award
Apr 30, 2008 09:40 AM | SIRT
- BellwetherReport.com Initiates Analyst Coverage on BRCM, ANAD, SIRT and REST
Apr 23, 2008 12:26 PM | ANAD, BRCM, REST, SIRT
- GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in 'Sirtuin' Research and Development
Apr 22, 2008 04:37 PM | GSK, SIRT
- Sirtris Announces SRT501 Lowers Glucose in Twice-Daily Dosing Clinical Trial; Study Suggests Dose Response for Proprietary Formulation of Resveratrol in Type 2 Diabetics
Apr 17, 2008 08:11 AM | SIRT
- Sirtris Scientific Advisory Board Co-Chairs Publish First In-Vivo Data Showing SIRT1 Enzyme Can Suppress Tumor Development
Apr 16, 2008 08:04 AM | SIRT
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
SIRT
|
Compare to S&P
|
| YTD |
-0.01 %
|
-0.01 %
|
| 4 Weeks |
-0.01 %
|
-0.01 %
|
| 12 Weeks |
-0.01 %
|
-0.01 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 0.00 %
|
|
EPS Growth in Last Year: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
